KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+6.89%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$226M
AUM Growth
+$226M
(-20%)
Cap. Flow
-$63.2M
Cap. Flow
% of AUM
-28.02%
Top 10 Holdings %
Top 10 Hldgs %
96.72%
Holding
13
New
1
Increased
4
Reduced
7
Closed
1
Top Buys
| 1 |
BioNTech
BNTX
|
$11.1M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$6.67M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$139K |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
$59.9K |
| 5 |
Sanofi
SNY
|
$27.2K |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$33.5M |
| 2 |
Alkermes
ALKS
|
$17.9M |
| 3 |
United Therapeutics
UTHR
|
$10.1M |
| 4 |
Exelixis
EXEL
|
$7.9M |
| 5 |
Biogen
BIIB
|
$5.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Exelixis
EXEL
$10.1B
| $37.2M | 16.48% | 1,566,140 -332,939 | -18% | -$7.9M |
|
|
2
United Therapeutics
UTHR
$13.8B
| $36M | 15.96% | 156,714 -44,158 | -22% | -$10.1M |
|
|
3
Biogen
BIIB
$19.4B
| $28.9M | 12.82% | 134,068 -26,412 | -16% | -$5.7M |
|
|
TARO
4
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $27.4M | 12.16% | 647,868 +1,415 | +0.2% | +$59.9K |
|
5
Cardinal Health
CAH
$35.5B
| $26.4M | 11.69% | 235,656 -45,820 | -16% | -$5.13M |
|
|
6
Enanta Pharmaceuticals
ENTA
$180M
| $19.6M | 8.71% | 1,124,586 +381,762 | +51% | +$6.67M |
|
|
7
Jazz Pharmaceuticals
JAZZ
$7.75B
| $12.2M | 5.4% | 101,151 +1,151 | +1% | +$139K |
|
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $12M | 5.33% | 12,494 -34,762 | -74% | -$33.5M |
|
|
9
BioNTech
BNTX
$24B
| $11.1M | 4.91% | +120,000 | New | +$11.1M |
|
|
10
Sanofi
SNY
$121B
| $7.34M | 3.25% | 150,959 +559 | +0.4% | +$27.2K |
|
|
11
Alkermes
ALKS
$4.78B
| $6.97M | 3.09% | 257,554 -660,484 | -72% | -$17.9M |
|
12
Mural Oncology
MURA
$35.7M
| $430K | 0.19% | 88,001 -2,832 | -3% | -$13.8K |
|
13
Masimo
MASI
$7.59B
| – | – | -8,000 | Closed | -$938K |
|